Abstract
5-Fluorouracil (5-FU) is one of the most potent antimetabolites which have been widely used in the treatment of advanced solid tumors. As an anticancer agent, because of its low efficacy and high toxicity, numerous modifications of 5-FU structure have been performed. A great number of novel 5-FU derivatives have been developed with highly efficient and much less toxic. In this paper, the recent development of novel 5-FU derivatives as potent antitumor agents is reviewed and discussed.
Keywords: 5-Fluorouracil (5-FU), anticancer, thymidylate synthase, antimetabolite, toxicity, tumor, derivative, macromolecule, pyrimidine, polymer
Current Medicinal Chemistry
Title: Development of 5-Fluorouracil Derivatives as Anticancer Agents
Volume: 18 Issue: 29
Author(s): Xiaoyan Pan, Chen Wang, Fang Wang, Pengfei Li, Zhigang Hu, Yuanyuan Shan and Jie Zhang
Affiliation:
Keywords: 5-Fluorouracil (5-FU), anticancer, thymidylate synthase, antimetabolite, toxicity, tumor, derivative, macromolecule, pyrimidine, polymer
Abstract: 5-Fluorouracil (5-FU) is one of the most potent antimetabolites which have been widely used in the treatment of advanced solid tumors. As an anticancer agent, because of its low efficacy and high toxicity, numerous modifications of 5-FU structure have been performed. A great number of novel 5-FU derivatives have been developed with highly efficient and much less toxic. In this paper, the recent development of novel 5-FU derivatives as potent antitumor agents is reviewed and discussed.
Export Options
About this article
Cite this article as:
Pan Xiaoyan, Wang Chen, Wang Fang, Li Pengfei, Hu Zhigang, Shan Yuanyuan and Zhang Jie, Development of 5-Fluorouracil Derivatives as Anticancer Agents, Current Medicinal Chemistry 2011; 18 (29) . https://dx.doi.org/10.2174/092986711797287584
DOI https://dx.doi.org/10.2174/092986711797287584 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials